Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies

Z. S. Pavletic, S. S. Joshi, S. J. Pirruccello, S. R. Tarantolo, J. Kollath, E. C. Reed, P. J. Bierman, J. M. Vose, P. I. Warkentin, T. G. Gross, K. Nasrati, J. O. Armitage, A. Kessinger, M. R. Bishop

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ≤ 500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8+ ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8+ cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting.

Original languageEnglish (US)
Pages (from-to)33-41
Number of pages9
JournalBone marrow transplantation
Volume21
Issue number1
DOIs
StatePublished - Jan 1 1998

Fingerprint

Stem Cell Transplantation
Hematologic Neoplasms
Blood Cells
Lymphocyte Count
Lymphocytes
Granulocyte Colony-Stimulating Factor
Graft vs Host Disease
Survival
Transplants
CD4-CD8 Ratio
Lymphokines
Phytohemagglutinins
Methotrexate
Cyclosporine
Reference Values
Tissue Donors
Cytokines
T-Lymphocytes
Infection

Keywords

  • Allogeneic
  • Lymphocytes
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. / Pavletic, Z. S.; Joshi, S. S.; Pirruccello, S. J.; Tarantolo, S. R.; Kollath, J.; Reed, E. C.; Bierman, P. J.; Vose, J. M.; Warkentin, P. I.; Gross, T. G.; Nasrati, K.; Armitage, J. O.; Kessinger, A.; Bishop, M. R.

In: Bone marrow transplantation, Vol. 21, No. 1, 01.01.1998, p. 33-41.

Research output: Contribution to journalArticle

@article{7e4228e10e914bd494e14b394744b261,
title = "Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies",
abstract = "Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ≤ 500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8+ ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8+ cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting.",
keywords = "Allogeneic, Lymphocytes, Stem cell transplantation",
author = "Pavletic, {Z. S.} and Joshi, {S. S.} and Pirruccello, {S. J.} and Tarantolo, {S. R.} and J. Kollath and Reed, {E. C.} and Bierman, {P. J.} and Vose, {J. M.} and Warkentin, {P. I.} and Gross, {T. G.} and K. Nasrati and Armitage, {J. O.} and A. Kessinger and Bishop, {M. R.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1701037",
language = "English (US)",
volume = "21",
pages = "33--41",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies

AU - Pavletic, Z. S.

AU - Joshi, S. S.

AU - Pirruccello, S. J.

AU - Tarantolo, S. R.

AU - Kollath, J.

AU - Reed, E. C.

AU - Bierman, P. J.

AU - Vose, J. M.

AU - Warkentin, P. I.

AU - Gross, T. G.

AU - Nasrati, K.

AU - Armitage, J. O.

AU - Kessinger, A.

AU - Bishop, M. R.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ≤ 500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8+ ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8+ cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting.

AB - Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ≤ 500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8+ ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8+ cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting.

KW - Allogeneic

KW - Lymphocytes

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=17744412916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744412916&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701037

DO - 10.1038/sj.bmt.1701037

M3 - Article

C2 - 9486492

AN - SCOPUS:17744412916

VL - 21

SP - 33

EP - 41

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -